Single intravenous (IV) dose of human Low Density Lipoprotein Receptor (LDLR) Gene Therapy
Pre-clinicalUNKNOWN 0 views this week 0 watching💤 Quiet
Interest: 12/100
12
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Homozygous Familial Hypercholesterolemia (HoFH)
Conditions
Homozygous Familial Hypercholesterolemia (HoFH)
Trial Timeline
Sep 30, 2019 → Sep 29, 2025
NCT ID
NCT04080050About Single intravenous (IV) dose of human Low Density Lipoprotein Receptor (LDLR) Gene Therapy
Single intravenous (IV) dose of human Low Density Lipoprotein Receptor (LDLR) Gene Therapy is a pre-clinical stage product being developed by REGENXBIO for Homozygous Familial Hypercholesterolemia (HoFH). The current trial status is unknown. This product is registered under clinical trial identifier NCT04080050. Target conditions include Homozygous Familial Hypercholesterolemia (HoFH).
What happened to similar drugs?
1 of 17 similar drugs in Homozygous Familial Hypercholesterolemia (HoFH) were approved
Approved (1) Terminated (0) Active (16)
Hype Score Breakdown
Clinical
3
Activity
4
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04080050 | Pre-clinical | UNKNOWN |
Competing Products
20 competing products in Homozygous Familial Hypercholesterolemia (HoFH)